To accelerate translational cancer research so that precise, impactful and cost-effective treatments can benefit cancer patients, OICR has implemented a new Clinical Translation Pathway (CTP). The CTP will support practice-changing research in biomarkers, diagnostics and therapeutics that will advance early detection and intervention research and have a clear path to the clinic and clinical impact. It will focus on primary-diagnosed or early recurrent cancers. The pathway will be fueled by innovations emerging from OICR-supported research and from research originating from across the province of Ontario.
The CTP consists of separate funding streams that support preclinical, clinical, and convergent research. OICR is currently inviting applications for the following two funding streams:
Pre-Clinical Acceleration Team Awards (Pre-CATA): Supports pre-clinical projects with a clear path to the clinic, with a focus on pre-clinical development of biomarkers, diagnostics and therapeutics.
Funding available: $250,000 per year for up to three years. OICR anticipates supporting up to eight Pre-CATA projects.
Clinical Acceleration Team Awards (CATA): Supports early phase (I-II), prospective, biomarker-rich trials for clinical validation of biomarkers, diagnostics and therapeutics.
Funding available: $500,000 per year for up to three years. OICR anticipates supporting up to eight CATA trials.